Table 4 |
|||
|
Laboratory outcome measures for the placebo group presented as average [mean (SE)] changes from baseline for the time on active therapy (weeks 24 – 48) compared with the time on placebo (weeks 0–24). Baseline values are the average of weeks – 2 and 0 for 0 – 24 week analysis and the average of weeks 20 and 24 for 24 – 48 week analysis |
|||
| Weeks 0–24 |
Weeks 24–48 |
P |
|
|
|
|||
| HTLV-I proviral loada (log10 copies/105 PBMCs) |
+0.03 (0.10) |
-0.09 (0.08) |
0.50 |
| Total Lymphocytesb (106/L) |
+148.2 (58.0) |
-71.1 (63.1) |
0.02 |
| CD3 Lymphocytesb (106/L) |
+98.4 (63.4) |
+7.0 (39.2) |
0.28 |
| CD3b % |
+0.2 (2.8) |
+2.8 (2.0) |
0.22 |
| CD4b Lymphocytes (106/L) |
+32.6 (33.1) |
+30.4 (46.9) |
0.97 |
| CD4b % |
-1.2 (0.9) |
+3.6 (1.9) |
0.08 |
| CD8b Lymphocytes (106/L) |
+65.8 (31.3) |
-23.5 (13.7) |
0.04 |
| CD8b % |
+1.4 (1.2) |
-0.7 (1.1) |
0.16 |
| CD25a % |
-0.8 (1.8) |
-0.2 (1.3) |
0.82 |
| CD69a % |
+0.4 (1.3) |
-0.2 (3.0) |
0.89 |
| CD71a% |
-0.3 (1.0) |
+0.5 (1.3) |
0.76 |
| HLA-DR% |
-4.85 (4.0) |
+1.05 (2.3) |
0.40 |
|
|
|||
|
a Data only available on n = 6 due to missing baseline data b Data only available on n = 7 due to missing baseline data |
|||
|
Taylor et al. Retrovirology 2006 3:63 doi:10.1186/1742-4690-3-63 |
|||
